Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.33 |
| ▸ | TSPO | P30536 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28886365 | 0.88 | LMNA (0.44) | LMNAMMP1MMP2MMP3MMP8 | |
| SCHEMBL2097527 | 0.83 | LMNA (0.60) | LMNAMMP1MMP2MMP3MMP8 | |
| Hydrochloric Acid SCHEMBL10805157 | 0.83 | LMNA (0.35) | LMNAMMP1MMP2MMP3MMP8 | |
| SCHEMBL10803777 | 0.81 | DPP4 (0.50) | LMNAHSD17B10ALDH1A1 | |
| SCHEMBL17228542 | 0.80 | LMNA (0.46) | LMNAMMP1MMP2MMP3MMP8 | |
| SCHEMBL3352929 | 0.80 | ALDH1A1 (0.48) | CA12CA1CA9CA2ALOX15 | |
| SCHEMBL9516432 | 0.80 | MGLL (0.46) | LMNAMMP1MMP2MMP3MMP8 | |
| Propionamide SCHEMBL17925397 | 0.79 | LMNA (0.50) | LMNAMMP1MMP2MMP3MMP8 | |
| SCHEMBL2524087 | 0.77 | LMNA (0.61) | LMNAMMP1MMP2MMP3MMP8 | |
| SCHEMBL14190157 | 0.77 | LMNA (0.33) | LMNAALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120037794-A | Preparation method and application of solvent-resistant polyamide composite membrane | 南京工业大学 | 2025-05-27 | — | — | CN | claimed |
| CN-109336884-B | Method for synthesizing trametinib key intermediate | 安庆奇创药业有限公司 | 2021-02-05 | — | — | CN | claimed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | claimed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | claimed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | claimed |
| WO-2002006229-A2 | HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | claimed |
| CN-120037794-A | Preparation method and application of solvent-resistant polyamide composite membrane | 南京工业大学 | 2025-05-27 | — | — | CN | disclosed |
| CN-113462278-B | Varnish composition, method for producing polyimide resin, and additive | 东京应化工业株式会社 | 2024-06-07 | — | — | CN | disclosed |
| CN-116988179-A | Preparation method of stock solution coloring acrylic black fiber and fiber thereof | 河北吉藁化纤有限责任公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-116876096-A | Black color paste for acrylic fiber and preparation method thereof | 河北吉藁化纤有限责任公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-115594551-A | Accurate controlled-release film filled with temperature-sensitive polymer nanoparticles and application thereof | 山东农业大学（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-112755193-A | Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof | 德玛医药 | 2021-05-07 | — | — | CN | disclosed |
| CN-109336884-B | Method for synthesizing trametinib key intermediate | 安庆奇创药业有限公司 | 2021-02-05 | — | — | CN | disclosed |
| WO-2000055120-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | disclosed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | disclosed |
| WO-2000007991-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | disclosed |
| WO-2000007980-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999059959-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 1999-11-25 | — | — | WO | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | LMNA 2367/4885MMP1 2726/4885MMP2 2416/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | LMNA 1884/4885MMP1 2180/4885MMP2 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.